Mechanism of PI3K pathway in tumor immune microenvironment

Abstract

Li Yingjue, Lu Dan. Mechanism of PI3K pathway in tumor immune microenvironment[J]. Journal of International Oncology, 2022, 49(11): 677-680.

References37

[1]	Roma-Rodrigues C, Mendes R, Baptista PV, et al. Targeting tumor microenvironment for cancer therapy[J]. Int J Mol Sci, 2019, 20(4): 840. DOI: 10.3390/ijms20040840. doi:10.3390/ijms20040840
[2]	O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(3): 151-167. DOI: 10.1038/s41571-018-0142-8. doi:10.1038/s41571-018-0142-8pmid:30523282
[3]	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454. DOI: 10.1056/NEJMoa1200690. doi:10.1056/NEJMoa1200690
[4]	Wu X, Gu Z, Chen Y, et al. Application of PD-1 blockade in cancer immunotherapy[J]. Comput Struct Biotechnol J, 2019, 17: 661-674. DOI: 10.1016/j.csbj.2019.03.006. doi:10.1016/j.csbj.2019.03.006
[5]	Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies[J]. Cancer Cell, 2018, 33(4): 581-598. DOI: 10.1016/j.ccell.2018.03.005. doi:S1535-6108(18)30109-0pmid:29634946
[6]	Ramapriyan R, Caetano MS, Barsoumian HB, et al. Altered cancer metabolism in mechanisms of immunotherapy resistance[J]. Pharmacol Ther, 2019, 195: 162-171. DOI: 10.1016/j.pharmthera.2018.11.004. doi:10.1016/j.pharmthera.2018.11.004
[7]	du Rusquec P, Blonz C, Frenel JS, et al. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer[J]. Ther Adv Med Oncol, 2020, 12: 1758835920940939. DOI: 10.1177/1758835920940939. doi:10.1177/1758835920940939
[8]	Vanhaesebroeck B, Perry MWD, Brown JR, et al. PI3K inhibitors are finally coming of age[J]. Nat Rev Drug Discov, 2021, 20(10): 741-769. DOI: 10.1038/s41573-021-00209-1. doi:10.1038/s41573-021-00209-1pmid:34127844
[9]	Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease[J]. Cell, 2017, 170(4): 605-635. DOI: 10.1016/j.cell.2017.07.029. doi:S0092-8674(17)30865-6pmid:28802037
[10]	Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46. DOI: 10.1158/2159-8290.CD-21-1059. doi:10.1158/2159-8290.CD-21-1059pmid:35022204
[11]	Liu M, Wei F, Wang J, et al. Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1^-PD-L1⁺Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer[J]. Cell Death Dis, 2021, 12(5): 465. DOI: 10.1038/s41419-021-03745-1. doi:10.1038/s41419-021-03745-1
[12]	Farhood B, Najafi M, Mortezaee K. CD8⁺cytotoxic T lymphocytes in cancer immunotherapy: a review[J]. J Cell Physiol, 2019, 234(6): 8509-8521. DOI: 10.1002/jcp.27782. doi:10.1002/jcp.27782pmid:30520029
[13]	Xiang X, Wang J, Lu D, et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy[J]. Signal Transduct Target Ther, 2021, 6(1): 75. DOI: 10.1038/s41392-021-00484-9. doi:10.1038/s41392-021-00484-9
[14]	Kaneda MM, Messer KS, Ralainirina N, et al. PI3Kγ is a molecular switch that controls immune suppression[J]. Nature, 2016, 539(7629): 437-442. DOI: 10.1038/nature19834. doi:10.1038/nature19834
[15]	Kaneda MM, Cappello P, Nguyen AV, et al. Macrophage PI3Kγ drives pancreatic ductal adenocarcinoma progression[J]. Cancer Discov, 2016, 6(8): 870-885. DOI: 10.1158/2159-8290.CD-15-1346. doi:10.1158/2159-8290.CD-15-1346pmid:27179037
[16]	Yang C, Chen C, Xiao Q, et al. Relationship between PTEN and angiogenesis of esophageal squamous cell carcinoma and the underlying mechanism[J]. Front Oncol, 2021, 11: 739297. DOI: 10.3389/fonc.2021.739297. doi:10.3389/fonc.2021.739297
[17]	Shen M, Wang J, Yu W, et al. A novel MDSC-induced PD-1^-PD-L1⁺B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties[J]. Oncoimmunology, 2018, 7(4): e1413520. DOI: 10.1080/2162402X.2017.1413520. doi:10.1080/2162402X.2017.1413520
[18]	Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity[J]. Nat Rev Immunol, 2021, 21(8): 485-498. DOI: 10.1038/s41577-020-00490-y. doi:10.1038/s41577-020-00490-ypmid:33526920
[19]	Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors[J]. Nat Med, 2014, 20(6): 607-615. DOI: 10.1038/nm.3541. doi:10.1038/nm.3541pmid:24793239
[20]	Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment[J]. Science, 2015, 348(6230): 74-80. DOI: 10.1126/science.aaa6204. doi:10.1126/science.aaa6204pmid:25838376
[21]	Chang CZ, Wu SC, Chang CM, et al. Arctigenin, a potent ingre-dient of Arctium lappa L., induces endothelial nitric oxide synthase and attenuates subarachnoid hemorrhage-induced vasospasm through PI3K/Akt pathway in a rat model[J]. Biomed Res Int, 2015, 2015: 490209. DOI: 10.1155/2015/490209. doi:10.1155/2015/490209
[22]	Shen W, Li HL, Liu L, et al. Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer[J]. Eur Rev Med Pharmacol Sci, 2017, 21(11): 2596-2603.
[23]	Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy[J]. Cancer Discov, 2016, 6(2): 202-216. DOI: 10.1158/2159-8290.CD-15-0283. doi:10.1158/2159-8290.CD-15-0283pmid:26645196
[24]	Lastwika KJ, Wilson W 3rd, Li QK, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer[J]. Cancer Res, 2016, 76(2): 227-238. DOI: 10.1158/0008-5472.CAN-14-3362. doi:10.1158/0008-5472.CAN-14-3362pmid:26637667
[25]	Gao Y, Yang J, Cai Y, et al. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling[J]. Int J Cancer, 2018, 143(4): 931-943. DOI: 10.1002/ijc.31357. doi:10.1002/ijc.31357pmid:29516506
[26]	Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3): 434-452. DOI: 10.1016/j.immuni.2018.03.014. doi:S1074-7613(18)30090-6pmid:29562194
[27]	Yao X, Tu Y, Xu Y, et al. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages[J]. J Cell Mol Med, 2020, 24(17): 9560-9573. DOI: 10.1111/jcmm.15367. doi:10.1111/jcmm.15367
[28]	Mansour FA, Al-Mazrou A, Al-Mohanna F, et al. PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis[J]. Oncoimmunology, 2020, 9(1): 1729299. DOI: 10.1080/2162402X.2020.1729299. doi:10.1080/2162402X.2020.1729299
[29]	Li X, Wenes M, Romero P, et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(7): 425-441. DOI: 10.1038/s41571-019-0203-7. doi:10.1038/s41571-019-0203-7pmid:30914826
[30]	Scharping NE, Menk AV, Moreci RS, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction[J]. Immunity, 2016, 45(3): 701-703. DOI: 10.1016/j.immuni.2016.08.009. doi:S1074-7613(16)30333-8pmid:27653602
[31]	Lim S, Liu H, Madeira da Silva L, et al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1α[J]. Cancer Res, 2016, 76(8): 2231-2242. DOI: 10.1158/0008-5472.CAN-15-1538. doi:10.1158/0008-5472.CAN-15-1538pmid:27197253
[32]	Katheder NS, Khezri R, O'Farrell F, et al. Microenvironmental autophagy promotes tumour growth[J]. Nature, 2017, 541(7637): 417-420. DOI: 10.1038/nature20815. doi:10.1038/nature20815
[33]	Verhoeven J, Baelen J, Agrawal M, et al. Endothelial cell autophagy in homeostasis and cancer[J]. FEBS Lett, 2021, 595(11): 1497-1511. DOI: 10.1002/1873-3468.14087. doi:10.1002/1873-3468.14087pmid:33837545
[34]	Janku F, McConkey DJ, Hong DS, et al. Autophagy as a target for anticancer therapy[J]. Nat Rev Clin Oncol, 2011, 8(9): 528-539. DOI: 10.1038/nrclinonc.2011.71. doi:10.1038/nrclinonc.2011.71pmid:21587219
[35]	Xu Z, Han X, Ou D, et al. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy[J]. Appl Microbiol Biotechnol, 2020, 104(2): 575-587. DOI: 10.1007/s00253-019-10257-8. doi:10.1007/s00253-019-10257-8pmid:31832711
[36]	Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-Ⅰ[J]. Nature, 2020, 581(7806): 100-105. DOI: 10.1038/s41586-020-2229-5. doi:10.1038/s41586-020-2229-5
[37]	Jabbarzadeh Kaboli P, Salimian F, Aghapour S, et al. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer—a comprehensive review from chemotherapy to immunotherapy[J]. Pharmacol Res, 2020, 156: 104806. DOI: 10.1016/j.phrs.2020.104806. doi:10.1016/j.phrs.2020.104806

Mechanism of PI3K pathway in tumor immune microenvironment

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References37

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[12]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[13]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[14]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[15]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.